kras mutation and glutathion KRAS-targeted therapies in cancer: novel approaches overcoming resistance Uncovering new therapeutic targets for
Uncovering new therapeutic targets for a common KRAS mutation behind cancer KRAS mutation: from undruggable to druggable in cancer Signal Transduction and Targeted Therapy KRAS OriGene Technologies Inc. BRAFV600E in colorectal cancer reduces sensitivity to oxidative stress and promotes site specific metastasis by stimulating glutathione synthesis: Cell Reports Rerouting the drug response: Overcoming metabolic adaptation in KRAS mutant cancers Science Signaling
Pay in 4 interest-free payments of $6.69 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9




